Preferred Label : fluticasone furoate;
MeSH note : a glucocorticoid; structure in first source;
Is substance : O;
UNII : JS86977WNV;
InChIKey : XTULMSXFIHGYFS-VLSRWLAYSA-N;
Origin ID : C523187;
UMLS CUI : C1948374;
ATC code(s)
- ATC code(s)
- CISMeF manual mappings
- Manual NTBT mappings (CISMeF)
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3528756/fr/fluticasone-furoate-teva-furoate-de-fluticasone-rhinite-allergique
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, intranasal
fluticasone furoate
evaluation of the transparency committee
Fluticasone
Rhinitis, Allergic
fluticasone furoate
---
https://www.has-sante.fr/jcms/p_3332764/fr/elebrato-ellipta-furoate-de-fluticasone-/-bromure-d-umeclidinium-/-trifenatate-de-vilanterol-bpco
2022
false
false
false
France
drug combinations
vilanterol, umeclidinium bromide and fluticasone furoate
fluticasone furoate
umeclidinium
pulmonary disease, chronic obstructive
evaluation of the transparency committee
vilanterol
---
https://www.has-sante.fr/jcms/p_3191669/fr/revinty-ellipta
2020
false
false
false
France
drug combinations
fluticasone furoate
vilanterol
fluticasone furoate-vilanterol trifenatate
vilanterol and fluticasone furoate
evaluation of the transparency committee
androstadienes
benzyl alcohols
chlorobenzenes
drug combinations
---
https://www.has-sante.fr/jcms/p_3191663/fr/relvar-ellipta
2020
false
false
false
France
drug combinations
fluticasone furoate
vilanterol
fluticasone furoate-vilanterol trifenatate
vilanterol and fluticasone furoate
evaluation of the transparency committee
androstadienes
benzyl alcohols
chlorobenzenes
drug combinations
---
https://www.has-sante.fr/portail/jcms/c_2964750/fr/elebrato-ellipta-trelegy-ellipta
2019
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/temybric-ellipta
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
fluticasone furoate
fluticasone furoate
glucocorticoids
glucocorticoids
umeclidinium
umeclidinium
muscarinic antagonists
muscarinic antagonists
vilanterol
vilanterol
pulmonary disease, chronic obstructive
product surveillance, postmarketing
vilanterol, umeclidinium bromide and fluticasone furoate
administration, inhalation
adult
aged
drug interactions
pregnancy
breast feeding
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
drug evaluation, preclinical
GSK573719
GSK573719
quinuclidines
quinuclidines
androstadienes
androstadienes
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes
---
https://www.has-sante.fr/portail/jcms/c_2964753/fr/elebrato-ellipta-trelegy-ellipta
2019
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
---
https://www.has-sante.fr/portail/jcms/c_2885118/fr/avamys
2018
false
true
false
France
administration, intranasal
rhinitis, allergic, seasonal
rhinitis, allergic, perennial
anti-inflammatory agents
fluticasone furoate
evaluation of the transparency committee
fluticasone furoate
androstadienes
---
https://www.has-sante.fr/portail/jcms/c_2862997/fr/relvar-ellipta-revinty-ellipta
2018
false
France
French
vilanterol
fluticasone furoate
drug combinations
treatment outcome
glucocorticoids
asthma
adult
adolescent
administration, inhalation
adrenergic beta-2 receptor agonists
androstadienes
benzyl alcohols
chlorobenzenes
vilanterol and fluticasone furoate
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
evaluation of the transparency committee
insurance, health, reimbursement
fluticasone furoate-vilanterol trifenatate
drug combinations
---
https://www.has-sante.fr/portail/jcms/c_2847883/fr/elebrato-trelegy-ellipta
2018
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
---
Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol
https://www.ema.europa.eu/medicines/human/EPAR/Trelegy-Ellipta
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
vilanterol, umeclidinium bromide and fluticasone furoate
drug approval
europe
treatment outcome
vilanterol
fluticasone furoate
drug combinations
umeclidinium
glucocorticoids
glucocorticoids
muscarinic antagonists
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
bronchodilator agents
bronchodilator agents
administration, inhalation
product surveillance, postmarketing
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes
androstadienes
---
Elebrato Ellipta - fluticasone furoate / umeclidinium / vilanterol
https://www.ema.europa.eu/medicines/human/EPAR/Elebrato-Ellipta
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
vilanterol, umeclidinium bromide and fluticasone furoate
drug approval
europe
treatment outcome
vilanterol
fluticasone furoate
drug combinations
umeclidinium
glucocorticoids
glucocorticoids
muscarinic antagonists
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
bronchodilator agents
bronchodilator agents
administration, inhalation
product surveillance, postmarketing
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes
androstadienes
---
https://minerva-ebp.be/FR/Article/2085
2017
false
false
false
false
Belgium
French
critical appraisal or critical reading
comparative study
fluticasone furoate
vilanterol
pulmonary disease, chronic obstructive
cardiovascular risk
cardiovascular diseases
placebos
androstadienes
benzyl alcohols
chlorobenzenes
---
http://www.has-sante.fr/portail/jcms/c_2754734/fr/revinty-ellipta
2017
false
false
false
France
French
treatment outcome
vilanterol
fluticasone furoate
drug combinations
vilanterol and fluticasone furoate
adult
pulmonary disease, chronic obstructive
administration, inhalation
glucocorticoids
bronchodilator agents
adrenergic beta-2 receptor agonists
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
evaluation of the transparency committee
insurance, health, reimbursement
benzyl alcohols
chlorobenzenes
androstadienes
---
https://www.ema.europa.eu/medicines/human/EPAR/Revinty-Ellipta
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
vilanterol
fluticasone furoate
fluticasone furoate
vilanterol
drug combinations
drug approval
europe
vilanterol and fluticasone furoate
asthma
child
adolescent
adult
pulmonary disease, chronic obstructive
administration, inhalation
glucocorticoids
glucocorticoids
bronchodilator agents
bronchodilator agents
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
drug monitoring
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
clinical trials as topic
drug evaluation, preclinical
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
benzyl alcohols
chlorobenzenes
androstadienes
androstadienes
benzyl alcohols
chlorobenzenes
---
https://www.ema.europa.eu/medicines/human/EPAR/Relvar-Ellipta
2013
false
United Kingdom
French
English
vilanterol
fluticasone furoate
drug combinations
drug approval
europe
treatment outcome
fluticasone furoate
glucocorticoids
glucocorticoids
vilanterol
asthma
adult
adolescent
pulmonary disease, chronic obstructive
summary of product characteristics
package leaflet
drug evaluation
syndication feed
administration, inhalation
product surveillance, postmarketing
drug monitoring
drug interactions
pregnancy
breast feeding
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
clinical trials, phase iii as topic
drug evaluation, preclinical
androstadienes
androstadienes
benzyl alcohols
benzyl alcohols
chlorobenzenes
chlorobenzenes
vilanterol and fluticasone furoate
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
fluticasone furoate-vilanterol trifenatate
fluticasone furoate-vilanterol trifenatate
drug combinations
drug combinations
---
http://www.has-sante.fr/portail/jcms/c_657772/avamys
http://www.has-sante.fr/portail/jcms/c_1648975/fr/avamys
http://www.has-sante.fr/portail/jcms/c_1648974/fr/avamys-04092013-avis-ct12744
2013
France
French
corticosteroid therapy
androstadienes
administration, intranasal
insurance, health, reimbursement
adult
adolescent
child
rhinitis, allergic, seasonal
rhinitis, allergic, perennial
treatment outcome
androstadienes
anti-inflammatory agents
anti-inflammatory agents
fluticasone furoate
fluticasone furoate
fluticasone furoate
evaluation of the transparency committee
nasal sprays
---
Summary Basis of Decision (SBD) for Breo Ellipta
100 µg of fluticasone furoate and 25 µg of vilanterol (as vilanterol trifenatate)
Powder, oral inhalation
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00174
2013
false
Canada
French
English
vilanterol and fluticasone furoate
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
drug information
Respiratory form fluticasone + vilanterol (product)
drug approval
canada
fluticasone furoate
fluticasone furoate
drug combinations
glucocorticoids
glucocorticoids
vilanterol
vilanterol
administration, inhalation
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
bronchodilator agents
bronchodilator agents
treatment outcome
drug evaluation
anti-inflammatory agents
anti-inflammatory agents
clinical trials, phase iii as topic
risk assessment
androstadienes
androstadienes
benzyl alcohols
benzyl alcohols
chlorobenzenes
chlorobenzenes
---
https://www.ema.europa.eu/medicines/human/EPAR/Avamys
2012
United Kingdom
English
French
syndication feed
androstadienes
treatment outcome
drug evaluation
drug labeling
drug approval
rhinitis, allergic, seasonal
adult
adolescent
rhinitis, allergic, perennial
administration, intranasal
anti-allergic agents
anti-allergic agents
child
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
androstadienes
fluticasone furoate
fluticasone furoate
androstadienes
summary of product characteristics
package leaflet
drug evaluation
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00012
2011
false
false
false
Canada
drug information
fluticasone furoate
metered dose inhalers
---
https://www.ema.europa.eu/medicines/human/EPAR/Alisade
2011
United Kingdom
French
English
syndication feed
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
fluticasone furoate
fluticasone furoate
androstadienes
drug approval
drug labeling
treatment outcome
rhinitis, allergic, seasonal
rhinitis, allergic, perennial
adult
child
adolescent
glucocorticoids
glucocorticoids
drug interactions
pregnancy
breast feeding
administration, intranasal
androstadienes
fluticasone furoate
androstadienes
drug evaluation
package leaflet
summary of product characteristics
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66921927
2008
France
French
suspensions
androstadienes
administration, intranasal
fluticasone furoate
fluticasone furoate
nasal sprays
drug information
---
